These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35611997)

  • 21. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
    Takahashi T; Illamola SM; Jennissen CA; Long SE; Lund TC; Orchard PJ; Gupta AO; Long-Boyle JR
    Transplant Cell Ther; 2022 Feb; 28(2):104.e1-104.e7. PubMed ID: 34883294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
    de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
    Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
    Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
    Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times.
    Kim Y; Moon S; Rhee SJ
    Drug Des Devel Ther; 2024; 18():871-879. PubMed ID: 38524879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
    Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron Chelation With Deferasirox Increases Busulfan AUC During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation.
    Essmann S; Dadkhah A; Janson D; Wolschke C; Ayuk F; Kröger NM; Langebrake C
    Transplant Cell Ther; 2022 Feb; 28(2):115.e1-115.e5. PubMed ID: 34775147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
    Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
    Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
    Trame MN; Bartelink IH; Boos J; Boelens JJ; Hempel G
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1149-55. PubMed ID: 24036908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
    Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
    Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
    Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
    Bone Marrow Transplant; 2001 Oct; 28(7):657-64. PubMed ID: 11704788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
    Shukla P; Goswami S; Keizer RJ; Winger BA; Kharbanda S; Dvorak CC; Long-Boyle J
    Front Pharmacol; 2020; 11():888. PubMed ID: 32714184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
    Veal GJ; Nguyen L; Paci A; Riggi M; Amiel M; Valteau-Couanet D; Brock P; Ladenstein R; Vassal G
    Eur J Cancer; 2012 Nov; 48(16):3063-72. PubMed ID: 22742881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.